Raxibacumab: potential role in the treatment of inhalational anthrax

References

• US Food and Drug AdministrationFDA approves raxibacumab to treat inhalational anthrax2012 Available from: http://www.fda.gov/News-Events/Newsroom/PressAnnouncements/ucm332341.htmAccessed January 10, 2014
   Google Scholar
• US Food and Drug AdministrationFDA-approved drug products2012 Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfoAccessed January 10, 2014
   Google Scholar
• US Food and Drug Administration, Department of Health and Human ServicesNew drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final ruleFed Regist200267105379883799812049094
   PubMedGoogle Scholar
• MeadowsMProject Bioshield: protecting Americans from terrorismFDA Consum2004386323315675025
   PubMedGoogle Scholar
• RussellPKProject BioShield: what it is, why it is needed, and its accomplishments so farClin Infect Dis200745Suppl 1S68S7217582574
   PubMed Web of Science ®Google Scholar
• InglesbyTVO’TooleTHendersonDAAnthrax as a biological weapon, 2002: updated recommendations for managementJAMA2002287172236225211980524
   PubMed Web of Science ®Google Scholar
• WrightJGQuinnCPShadomySMessonnierNCenters for Disease Control and PreventionUse of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009MMWR Recomm Rep201059RR–613020651644
   PubMedGoogle Scholar
• JerniganJAStephensDSAshfordDABioterrorism-related inhalational anthrax: the first 10 cases reported in the United StatesEmerg Infect Dis20017693394411747719
   PubMed Web of Science ®Google Scholar
• WalshJJPesikNQuinnCPA case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factorClin Infect Dis200744796897117342650
   PubMed Web of Science ®Google Scholar
• JefferdsMDLasersonKFryAMAdherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, DC, 2001Emerg Infect Dis20028101138114412396929
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionExpert panel meetings on prevention and treatment of anthrax in adults2014 Available from: http://wwwnc.cdc.gov/eid/article/20/2/13-0687_article.htmAccessed March 6, 2014
   Google Scholar
• CoteCKWelkosSLBozueJKey aspects of the molecular and cellular basis of inhalational anthraxMicrobes Infect20111314–151146115521816231
   PubMed Web of Science ®Google Scholar
• HicksCWSweeneyDACuiXLiYEichackerPQAn overview of anthrax infection including the recently identified form of disease in injection drug usersIntensive Care Med20123871092110422527064
   PubMed Web of Science ®Google Scholar
• SweeneyDAHicksCWCuiXLiYEichackerPQAnthrax infectionAm J Respir Crit Care Med2011184121333134121852539
   PubMed Web of Science ®Google Scholar
• ReadTDPetersonSNTourasseNBaillieLWPaulsenITNelsonKEThe genome sequence of Bacillus anthracis Ames and comparison to closely related bacteriaNature20034236935818612721629
   PubMed Web of Science ®Google Scholar
• MakinoSUchidaITerakadoNSasakawaCYoshikawaMMolecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracisJ Bacteriol198917127227302536679
   PubMed Web of Science ®Google Scholar
• Piris-GimenezACorreJPJouvionGCandelaTKhunHGoossensPLEncapsulated Bacillus anthracis interacts closely with liver endotheliumJ Infect Dis200920091381138919785525
   PubMed Web of Science ®Google Scholar
• BradleyKAMogridgeJMourezMCollierRJYoungJAIdentification of the cellular receptor for anthrax toxinNature2001414686022522911700562
   PubMed Web of Science ®Google Scholar
• CollierRJMembrane translocation by anthrax toxinMol Aspects Med200930641342219563824
   PubMed Web of Science ®Google Scholar
• ChitlaruTAltboumZReuvenySShaffermanAProgress and novel strategies in vaccine development and treatment of anthraxImmunol Rev2011239122123621198675
   PubMed Web of Science ®Google Scholar
• LepplaSHAnthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cellsProc Natl Acad Sci U S A19827910316231666285339
   PubMed Web of Science ®Google Scholar
• BarakatLAQuentzelHLJerniganJAFatal inhalational anthrax in a 94-year-old Connecticut womanJAMA2002287786386811851578
   PubMed Web of Science ®Google Scholar
• MinaBDymJPKuepperFFatal inhalational anthrax with unknown source of exposure in a 61-year-old woman in New York CityJAMA2002287785886211851577
   PubMed Web of Science ®Google Scholar
• AgrawalALingappaJLepplaSHImpairment of dendritic cells and adaptive immunity by anthrax lethal toxinNature2003424694632933412867985
   PubMed Web of Science ®Google Scholar
• FangHXuLChenTYCyrJMFruchtDMAnthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin productionJ Immunol2006176106155616116670324
   PubMed Web of Science ®Google Scholar
• BushLMAbramsBHBeallAJohnsonCCIndex case of fatal inhalational anthrax due to bioterrorism in the United StatesN Engl J Med2001345221607161011704685
   PubMed Web of Science ®Google Scholar
• MigoneTSSubramanianGMZhongJRaxibacumab for the treatment of inhalational anthraxN Engl J Med2009361213514419587338
   PubMed Web of Science ®Google Scholar
• [No authors listed]Raxibacumab for anthraxMed Lett Drugs Ther2013551413272823545582
   PubMed Web of Science ®Google Scholar
• MazumdarSRaxibacumabMAbs20091653153820068396
   PubMed Web of Science ®Google Scholar
• ChenZMoayeriMPurcellRMonoclonal antibody therapies against anthraxToxins (Basel)2011381004101922069754
   PubMed Web of Science ®Google Scholar
• SubramanianGMCroninPWPoleyGA phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteersClin Infect Dis2005411122015937757
   PubMed Web of Science ®Google Scholar
• CuiXLiYMoayeriMLate treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsisJ Infect Dis2005191342243415633102
   PubMed Web of Science ®Google Scholar
• CoreyAMigoneTSBolmerSBacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/raxibacumab-treated New Zealand white rabbitsToxins (Basel)20135112013823344456
   PubMed Web of Science ®Google Scholar
• MytleNHopkinsRJMalkevichNVEvaluation of intravenous anthrax immune globulin for treatment of inhalation anthraxAntimicrob Agents Chemother201357115684569223979731
   PubMed Web of Science ®Google Scholar